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1. Introduction 
Meningiomas as extra axial tumours, developing from arachnoid cap cells may occur from 
all dural structures, cranial and spinal and rarely outside of these structures (Whittle et al. 
2004). The skull base is an area with multiple neural structures as well as brain supplying 
adjacent arteries and veins. Meningiomas, growing on or within the skull can thus be very 
challenging for the neurosurgeon. In consequence, complete tumour removal without 
neural impairment is not always possible (Seifert 2010; Yasargil 1980) and surgery in this 
area, especially in petro-clival meningiomas, hazardous. Advances in microsurgical 
technique, development of new approaches and advancement of adjuvant therapies allow 
for reducing or removing meningiomas as well as a sufficient control of residual or 
recurrent tumours.  
2. Epidemiology 
Meningioma is considered the most primary intracranial neoplasm, representing 14.3-19.0% 
of all intracranial tumours. Hence, estimated prevalence is approximately 100/100.000 with 
an age adjusted, sex dependent incidence rate of 8.4 and 3.6/100.000 a year.  
According to the current WHO classification, the vast majority of these tumours are 
classified as grade I (aka benign meningioma, approximately 80-90%). With a distinct 
increase of recurrence and mortality, about 4.7 up to 20% of meningiomas are characterized 
as grade II (aka atypical) meningioma, while grade III (aka anaplastic) tumours occur in 1.0-
2.8% of all meningiomas (Louis et al. 2007). Although meningioma appears presumably in 
all groups of age with even infants being affected, incidence peaks markedly in the fourth 
and sixth decade (Chohan et al. 2011; Rockhill et al. 2007). Sex distribution depicts female 
pre-dominace among all groups of age with a distinct apex of almost 2:1 in the 30s and 40s 
(Rockhill et al. 2007; Whittle et al. 2004; Wiemels et al. 2010).  
3. Etiology 
Although most meningiomas occur presumably spontaneously and therefore independently 
of neither endogenous nor exogenous factors, high and low-dose ionizing cranial radiation 
could be shown to induce especially meningiomas of higher grades of malignancy (Louis et 
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al. 2007; Wiemels et al. 2010). Pronounced female predominance among patients in the 
fertile decades and various expression of progesterone, estrogen and androgen receptors 
suggest impact of sex hormones on tumour genesis and growth. Subsequently, a relation 
between the administration of oral contraceptives/ exogenous hormones (hormone 
replacement therapy, HRT) and an increased risk of meningioma development was 
observed (Michaud et al. 2010). Hence, these observations remain controversial and the role 
of sex hormones in tumour genesis needs to be determined in further analyses.  
About 20% of meningiomas in adults occur in patients suffering from neurofibromatosis 
type 1 (Wiemels et al. 2010). 
4. Locations 
Approximately one third of meningiomas are classified as typical skull base meningioma, 
subsuming tumours arising from the arachnoids of the olfactory groove (< 10%), the 
tuberculum sellae (12.8%), the foramen magnum (<4%) and the sphenoid ridge (17%). The 
least includes meningiomas arising from either the medial, clinoidal, alar or outer, 
temporal/pterional portion of the sphenoid ridge (30.1%, 6.9% and 16% of all meningiomas 
involving the sphenoid ridge, respectively) (Honig et al. 2010; Mendenhall et al. 2004; 
Condra et al. 1997; Rockhill et al. 2007).  
 
Fig. 1. Computed tomography of the scull base with marked areas of meningioma 
occurrence, A: olfactory groove, B: para- , suprasellar, C: petro-clival, D: sphenoid wing, E: 
foramen magnum. 
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5. Symptoms 
In general, unspecific symptoms like headache might occur years before a correct diagnosis. 
Contrarily to tumours of the convexity, seizures are rarely seen in skull base meningiomas. 
Amongst skull base meningiomas seizures mostly happen in cases of sphenoid wing tumours.  
5.1 Frontal skull base 
Meningiomas developing at the frontal skull base, especially in the olfactory groove can be 
of grotesque size (Fig. 2) before diagnosed, due to the fact that hypo- or anosmia, may occur 
very slowly and thus might not impact the patients’ life quality immediately.  When 
spreading along the midline and reaching the tuberculum sellae other neurological 
symptoms may occur. Affection of the fronto-basal lobe can induce incontinence as well as 
psychotic disturbances, e.g. personality changes, psycho-motor disabilities and cognitive 
impairment. Visual disturbances occur due to compression of the optic nerve (reduction of 
vision, blindness) or affection of the chiasm (bitemporal hemianopsia). Furthermore, the 
compression of the pituitary stalk and/or the hypothalamus can induce endocrinological 
disturbances. 
 
Fig. 2. T1-weighted triplanar magnetic resonance tomography after application of 
gadolinium, revealing a huge tuberculum sellae meningioma with homogenous contrast 
enhancement 
5.2 Sphenoid ridge 
Tumour growth along the sphenoid wing can cause a range of different neurological 
symptoms. When spreading into the middle skull groove, affecting the basal temporal lobe, 
seizures may be the first symptoms of the tumour. Furthermore, affection of the optic nerve 
can induce visual disturbance. Diplopia may occur due to compression of eye movement 
nerves (CN III, IV, VI), trigeminal nerve impairment may induce dysesthesia and/or loss of 
sensibility and ultimately even lead to a keratitis.  
Especially bone invading sphenoid wing meningiomas might cause hyperostosis (Bikmaz et 
al. 2007).  
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5.3 Petro-clival 
Tumour extension along the clivus may affect cranial nerves (CN V, VII-XI). According to 
the tumour mass and location (Fig. 3) occlusive hydrocephalus may occur as well as 
symptoms of brain stem compression (mono- or hemiparesis, paresthesia).   
 
Fig. 3. Magnetic resonance tomography (A: T1 weighted, B: T2 weighted, both after 
application of gadolinium), showing a right sided petro-clival meningioma. 
5.4 Foramen magnum 
Meningiomas growing within the foramen magnum, ventral, lateral or dorsal, may affect 
especially the lower CN as well as brain stem functions. In addition to that occlusive 
hydrocephalus due to compression of the aqueduct may occur. Furthermore, meningioma 
within the posterior fossa, growing from the tentorium may compress and/or invade the 
cerebral sinus or arteries.  
All tumours within the posterior fossa may irritate cerebellar functions, inducing ataxia, 
dysmetry, tremor and vertigo.  
6. Pre-operative management 
6.1 Neuro-imaging 
In most patients with acute symptoms like seizures, a native computed tomography will 
be performed. In case of suspected intracranial or intracerebral mass and in absence of 
contraindications, a contrast-CT can be added. While classical indications as 
calcifications, surrounding edema and hyperostosis are revealed by native CT, tumour 
extension is well documented by a contrast-CT (Fig. 4). Performing an angio-CT may 
reveal the correlation between meningioma and vessels (Fischer et al. 2009). Assuming a 
sinus invasion more information can be gathered by angiography, especially in a venous 
phase. 
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Fig. 4. Magnetic resonance tomography (coronar, T1-weighted, after application of 
gadolineum), showing A: a ventro-lateral  and B: a dorso-lateral foramen magnum 
meningioma. 
Magnetic resonance tomography including T1- and T2- weighted sequences, before and 
after contrast application, should be best practice in pre-operative meningioma diagnostic 
(Fig. 5).  
In highly vascularized meningioma the demonstration of vascular architecture, e.g. by 
digital subtraction angiography, might be indicated to prevent vascular damage (Dowd et 
al. 2003). In special cases embolization of feeding arteries reduces the risk of disproportional 
intra-operative bleeding. Yet, there is no distinct data stating a definite duration between 
embolization and surgery, preventing re-opening of arteries as well as vascular genesis, 
which can sweep off the embolization effect (Dowd et al.2003). 
 
Fig. 5. Computed tomography (A: native and B: with contrast) and magnetic resonance 
imaging, T1 weighted (C before and D after gadolinium ) revealing a huge tuberculum 
sellae meningeoma with central calcification and homogenous contrast enhancement (B, D). 
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6.1.1 Neuro-navigation 
Technical innovations, such as neuro-navigation and intraoperative ultrasound led to more 
efficient planning of the surgical approach, due to smaller skin incision and bone resection. 
As ultrasound may show subcortical tumour localisation and vascularitiy and especially the 
course of larger vessels and tumour extension can be detected more easily. Other than in 
patients with sub-cortical tumours, in scull base meningiomas no brain shift occurs since the 
tumour is fixed at dural or osseous structures. In consequence, neuro-navigation may show 
the size of the residual tumour and the distance to vascular, neural and osseous structures.  
For neuro-navigation 1 mm thick cranial CT-slices, scanned without gantry overturning, can 
be fusioned with MRI scans. This combination not only shows tumour mass, but also 
evidences vascular and neural structures as well as the extension within the osseous skull 
base.   
Depending on tumour location and encasement of each cranial nerve, patients should be 
informed thoroughly about potential transient or persisting postoperative cranial nerve 
dysfunction. Appropriation of blood products (erythrocytes, thrombocytes) should be 
managed preoperatively.  
6.2 Medication 
- Steroids (e.g. dexamethasone 4mg q 8 hrs) are recommended to reduce peri-tumoural 
brain edema and edema-induced neurological symptoms 
- Pre-operative application of anti-convulsive drugs is only indicated in patients with 
seizures and cannot be recommended prophylactically (Lieu&Howng 2000; Sughrue et 
al. 2011) 
- Due to the possible distinct vascularization, impaired coagulation (e.g. 
pharmacologically by platelet aggregation inhibitors or coumarins) should not be 
present at time of surgery (Sughrue et al. 2011) 
7. Approaches 
In most cases of skull base meningiomas surgery is the first choice treatment. The success of 
surgical intervention depends substantially on the right approach to the tumour and thus 
substantially on the localization of the tumour.  
Technical and medical advancement allow for the treatment of even deep or central seated 
meningiomas with low risk for peri-operative morbidity and mortality. 
Since there are no strict recommendations on how to get access to the tumour, knowing the 
location of adjacent eloquent brain areas, run of cranial nerves, arteries and veins is essential 
to determine the most efficient and safe approach. 
In this chapter we will describe some efficient approaches for treating skull base 
meningiomas of all kinds of localisations surgically. Anyways, best advice remains: “use the 
approaches you are familiar with”. 
In general, administration of hyperosmolaric fluids 30 min before skin incision, is 
recommended to all patients with skull base meningiomas unless there is no contraindication. 
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Fig. 6. Drawing of main approaches to meningiomas located in the olfactory groove, planum 
sphenoidale, para- and supra-sellar, sphenoid wing 
7.1 Olfactory groove-, tuberculum sellae- meningiomas 
In patients with olfactory groove meningiomas a fronto-basal craniotomy, mono- or 
bifrontal, and interhemispheric subfrontal approach is sufficient (Nakamura et al. 2006, 
2008). For an interhemispheric approach occlusion of the superior sagittal sinus is 
sometimes necessary. In most cases this occlusion is without squeals if performed in the 
frontal third. A pre-operative CT-scan or digital subtraction angiography can reveal 
bridging veins, leading to the superior sagittal sinus, which should be preserved. 
Dura opening should be semicircular with fronto-basal base.  
7.2 Tuberculum sellae-, planum sphenoidale- meningiomas  
Even though tuberculum sellae meningiomas are midline skull base tumours, the 
craniotomy for these tumours is placed supra-orbital reaching the tumour sub-frontally 
(Samii & Gerganov 2008). After dura opening, basal cisterns should be opened and CSF can 
be aspirated. Thus, by additional use of hyperosmolaric fluids and aspirating CSF the 
tumours can be reached with only slight retraction of the frontal lobe. 
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7.3 Sphenoid wing meningiomas 
For small medial sphenoid wing meningiomas a supra-orbital craniotomy or a subfrontal 
approach are mostly used. Due to the extension of the tumour the supra-orbital craniotomy 
can be expanded to a orbito-zygomatic or a fronto-temporal craniotomy (Mahmoud et al. 2010; 
Seckin et al. 2008). Dura opening and CSF leakage should be performed like shown above.  
Tuberculum sellae as well as sphenoid wing meningiomas sometimes invade the optic 
canal. In all cases of tumour extension into the optic canal, revealed by neuro-imaging pre-
operatively, the nerve should be unroofed and tumour mass removed (Mahmoud et al. 
2010). Otherwise swelling of residual tumour mass within the canal after closure of tumour 
vessels, especially veins, may deteriorate the visual faculty.  
7.4 Petro-clival meningiomas  
A multiplicity of approaches has been developed and is used today, depending on the 
extension of the tumour, the clinical status of the patient and especially the surgeon’s 
experience. These approaches not only involve pterional and orbitozygomatic craniotomies 
but also sub-occipital approaches, sometimes in combination with a petrosal approach 
(Bambakidis et al. 2007; Kandenwein et al. 2009; Samii & Gerganov 2008; Seifert 2010). 
In order to reach petroclival meningiomas, we recommend a sub-occipital craniotomy. 
Depending on tumour localization (ventral, lateral or dorsal) and size, these tumours often 
affect lower cranial nerves and/or the brain stem. To avoid cranial nerve and brain stem 
damage and get a better overview, the approach can be extended to a “far lateral approach”.  
For surgery of the posterior skull base, e.g. for suboccipital craniotomies, the patient is 
bedded in “parkbench-position” (Fig. 7). The endo-tracheal tube is combined with an 
electrode monitoring motor vagal nerve function.  
In case of dorsal foramen magnum meningioma a partial laminectomy of the atlas is 
performed, if necessary with partial resection of the lamina of the axis.  
In the pictures below craniotomy involves the foramen magnum as well as a partial 
resection of C1 in terms of partial laminectomy and mobilization of the vertebral artery (Fig. 
8). Dura opening can be stretched across the complete cranio- and laminectomy. By 
preparing and opening of basal cisterns CSF can be withdrawn by suction.  
A recently published comprehensive review on the outcome after surgery of petroclival 
meningeomas, stated no significant differences to the approach used (DiLuna & Bulsara 2010). 
8. Intra-operative management 
Skull base meningiomas often involve cranial nerves, brain arteries and might furthermore 
compresses the brain stem and/ or the spinal cord (DiLuna & Bulsara 2010). To avoid nerve 
and/or spinal cord injury, monitoring of nerve and spinal cord function is essential. In order to 
preserve motor cranial nerves electromyography should be recorded, furthermore visual, 
auditory, somato-sensory or motor evoked potentials should be monitored to avoid the nerve 
conduction (Topsakal et al. 2008). In all cases the efficiency of neuro-monitoring depends 
mainly on the kind of anaesthesia, therefore total intravenous anaesthesia should be used. 
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Fig. 7. For suboccipital approaches patients are bedded in park-bench position. 
 
Fig. 8. Reconstruction of cranial computed tomography demonstrating the far lateral 
approach, B is an excerpt of A. Yellow areas highlight the extend of craniotomy and hemi-
laminectomy of the atlas (open arrow), after mobilization of the vertebral artery (red arrow). 
The keyhole for suboccipital craniotomy is placed on the asterion (closed white arrow).   
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8.1 Tumourresection 
Since nervefibres may run within the capsule, in tumours affecting cranial nerves, these should 
be identified by neurostimulation to prevent neural deficit. Resection of the tumour then starts 
with opening of the tumour capsule and intracapsular debulking. To avoid damage of neural 
function due to traction and compression by manipulation, an ultrasound aspirator system is 
used. In many cases vascular supply of the tumour comes from arteries at the tumour basis 
and can not be cut off in the beginning of tumour resection. Furthermore, especially in 
petroclival meningiomas blood supplying arteries arising from different vascular territories 
have to be prepared carefully to prevent cerebellar or brain stem ischemia. Finally the capsule, 
after separation of nerves and vessels can be resected (Fig. 9). 
  
 
Fig. 9. Tri-planar, T1-weighted magnetic resonance imaging after gadolinium application, 
revealing nearly complete tumour removal (panel below) of the huge tuberculum sellae 
meningioma.  
Whenever cranial nerves as well as vessels hinder tumour overview, new technical tools 
such as endoscopy may help to identify tumour residuals, especially in petro-clival 
meningiomas (Samii & Gerganov 2008). In selected patients, especially with frontal and 
tuberculum sellae meningiomas, endoscopic tumour removal with extended transnasal, 
transsphenoidal surgery, or with small craniotomy, can be successfully performed 
(Rachinger et al. 2010; Wang et al. 2010). 
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Similar to non skull base meningiomas, the grade of tumour resection is classified by the 
Simson grading system 
 
Grade Degree of removal 
I 
Macroscopically complete resection, excision of adjacent abnormal dura or 
bone  
II 
Macroscopically complete resection, coagulation of adjacent abnormal dura or 
bone  
III 
Macroscopically complete resection, no coagulation or excision of adjacent 
abnormal dura or bone  
IV Partitial removal 
V Decompression 
Table 1. The Simpson grading system for removal of meningiomas (modified after Simpson 
1957).  
In different approaches, frontal, orbital, orbito-zytomatic as well as subocciptal, opening of 
frontal sinus or mastoid cells may occur. In such cases, mucosa has to be removed and the 
sinus as well as mastoid cells should be sealed with muscle or fat tissue and fixed with glue 
to avoid CSF leakage as well as inflammation. 
Dural closure should be waterproof to prevent CSF leakage and re-operation. If dura was 
resected because of tumour invasion, dura plastic should be performed in an optimal way 
with autologous material such as galeal-periosteal flap. 
9. Post-operative management  
Post-operatively patients should be observed on an intense care unit where frequent 
neurological examination and optional mechanical ventilation is assured. 
According to the extension of peri-tumoural edema steroid application should be continued 
for a few days, e.g. dexamethasone which is applicated 4mg q 8 hours the day of surgery 
and subsequently halved each following day.  
Up to 25 % of meningioma patients develop seizures and antiepileptic drugs might be 
present in a large number of patients. Since intraoperative mechanical manipulation of the 
tumour surrounding brain tissue might even provoke further cortical epileptic activity, 
preoperatively onset antiepileptic drugs should be pursued for a few weeks postoperatively 
as well (Lieu & Howng 2000; Sughrue et al. 2011; van Breemen et al. 2007). 
10. Adjuvant therapy 
10.1 Radiation therapy 
In patients with residual tumours as well as in patients with atypical or anaplastic 
meningiomas additional therapeutic options (radiotherapy, radiosurgery, e.g.) may help to 
control tumour growth and extension (Davidson et al. 2007; Minniti et al. 2009). With 
conventional fractionated radiotherapy, 50 – 55 Gy, admitted in 30 – 33 sessions, a local 
control rate is observed in about 80%, additionally tumour shrinking is seen in up to 25% 
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(Minniti et al. 2009). In cases of incomplete resected meningioma WHO grade I, adjuvant 
radiation therapy should be started if tumour re-growth is documented, whereas primary 
postoperative radiation therapy with 55 - 60 Gy should be initiated in patients with higher 
grade meningiomas, independent of resection grade. 
The kind of used radiation technique depends on tumour size and localization and the 
distance between tumour and neural structures as for example the optic system. In 
meningioma greater than 4 ml and with a distance of more than 2 mm between tumour and 
neural structures fractionated stereotactic radiotherapy seems to be more efficient for 
tumour control than radiosurgery (Deinsberger & Tidstrand 2005). 
Radiotherapy, e.g. radiosurgery, as first choice of treatment, may be indicated in patients 
not eligible for surgery due to co-morbidities, a tumour size less than 3 cm and/or tumour 
localization with high risk of intra- or post-operative vascular or neural damage (Davidson 
et al. 2007). 
10.2 Chemotherapy 
Medical therapy in patients with residual, inoperative or recurrent meningiomas has been 
subject of intense research. Due to the fact that meningiomas express progesterone 
receptors in up to 67% and somatostatin receptors in up to 100 %, chemotherapeutical 
studies focus on the development of receptor antagonists to stop tumor growth (Wen et 
al. 2010; Whittle et al. 2004). Yet, trials of various drugs have not been very successful 
(Norden et al. 2009, Schulz et al. 2011). Anyway, some data from ongoing and recently 
closed studies are still lacking, e.g. hydroxyurea (Norden et al. 2009; Newton et al. 2007). 
For additional therapeutic options such as receptor antagonists (vascular, angiogenesis, 
growth factor, hormones e.g.) the efficiency has to be revealed in clinical studies as well 
(Norden et al. 2009). 
In all patients neuro-imaging controls should be performed periodically, at its best by MRI, 
the first one 3 month after surgery.  
11. Outcome 
In one study 5 year post-operative survival of meningioma patients was specified up to 
91.3%. Anyway, recurrence rates and mortality are considerably affected by extent of 
surgical resection and histological grading. Analyses showed that WHO grade of skull base 
meningiomas is significantly lower as compared to their non skull base counterparts (Kane 
et al. 2011). Anyway, due to anatomical conditions resection of skull base meningioma still 
remains a surgical challenge and outcome is additionally affected by skills and experience of 
the treating surgeon as well as by exact tumour location and relation to adjacent anatomic 
structures. Subsequently, researching the literature reveals wide spreading postoperative 
morbidity and mortality rates.  
In a current series of 73 sphenoid ridge meningiomas (Honig et al. 2010), rates of 
perioperative morbidity and mortality were 7% and 3%, respectively, with 11 patients (15%) 
developing tumour recurrence (mean follow-up 29.8 months). In another series of 117 
foramen magnum meningiomas, perioperative mortality was 1.8%, recurrence rate among 
the 93 followed up patients was calculated for 1.1% (Wu et al. 2009). Concerning 
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meningiomas of the ventro-medial skull base, analyses revealed gross total resection 
(simpson I and II) in approximately 90% with a perioperative mortality of 2.8% and 
recurrence rates 4.9% for both olfactory groove and tuberculum sellae meningiomas 
(Nakamura et al. 2006, 2008; Spektor et al. 2005). Additionally, table 2 gives an overview 
depicting morbidity and mortality following surgery for skull base meningiomas basing on 
a review of Chen et al. which mainly included outcome reports published from 2000 to the 
present (Chen et al. 2011) . 
 
Location 
Rate of 
total 
excision 
Recurrence Morbidity Mortality 
Anterior fossa 85–100%  
0–4.9, mean follow-up of  
2–5.28 years 
0–31.3%  0–4.9%  
Tuberculum sellae 76.4– 93% 
1.4–4.2%, mean follow-up of 
2.5–4.3 years  
25–45%  0–8.7%  
Medial sphenoid ridge 58–87%  
0–9%, mean follow-up of  
3.1–12.8 years 
5.7–13%  0  
Clinoidal 
54.5–
86.7%  
3.8–15%, mean follow-up of 
3.1–4.5 years 
4–29%  0  
Middle fossa, 
Cavernous sinus 
0 
5–5.7%, mean follow-up of 
2.3–3.8 years 
7.5–15%  0  
Posterior fossa, 
Petroclival  
0–48%  
5–29%, mean follow-up of 
3.9–8.5 years 
20.3-47%  0–0.7%  
Cerebellopontine angle 82–86.1%  
3.9–7.5%, mean follow-up of 
3.0–6.0 years 
10.4–35.7%  0–5%  
Foramen magnum 67–96%  
0–5.5%, mean follow-up of 
3.6– 6.1 years 
5.9–27%  0–4.9%  
Jugular foramen 50–100% 
0–16.6%, mean follow-up of 
2.5–6.5 years 
30–61.5% 0–20% 
Tentorial  77–91.3%  
0–8.6%, mean follow-up of 
4.5–5.9 years 
9.7–55%  0–3.7%  
Table 2. Outcome after surgical resection of skull base meningiomas of different locations 
(modified after Chen et al. 2011). 
In order to estimate risk of meningioma surgery preoperatively, studies showed several 
predictors like patients’ age, co-morbidity, preoperative neurological deficit, tumour size 
and location (Caroli et al. 2005; Joung & Lee 2008). Considering skull base lesions, Adachi 
et al. developed an ABC Surgical Risk Scale introducing a scoring system including 
previous radiation or tumour surgery, tumour attachment size, arterial involvement, 
brainstem contact, central cavity location and cranial nerve group involvement as 
predictors for a worse neurological outcome (table 2). Thus, score reaches from 0 to 12 
points, which was subsequently graduated into low (0-4), moderate (5-7) and high (8-12 
points) risk group compared to extend to surgical resection and patients´ outcome (Tabl. 
3, Adachi et al. 2009). Although estimation of perioperative risk might still remain 
individual in most instances, this considerably depicts necessity of adequate preoperative 
imaging. 
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  Points 
    0 1 2 
A 
Attachment size <2cm 2-4cm >4cm 
Arterial involvement None Single Multiple 
B Brainstem contact 
CSF space 
visible 
No CSF space 
visible 
Perifokal 
edema 
C 
Central Cavity Outside 
Partitial 
involvement 
Inside 
Cranial nerve group 
involvement 
None One ≥2 
Table 3. The ABC Surgical Risk Scale for skull base meningioma CSF=Cerebrospinal fluid 
(modified after Adachi et al. 2009). 
12. Future directions 
Knowledge in underlying genetic alterations as well as in epigenetic pathologies is 
increasing and may help to identify genetic risk factors for tumour recurrence and 
malignancy (Bethke et al. 2008; Norden et al. 2009). Within the last years, new target 
therapy options such as hormone receptor antagonists and anti-angiogenetic drugs (e.g. 
bevacizumab) could be evaluated in meningioma therapy with partially results (Norden 
et al., Newton et al. 2007). Anyways, the role of such a specified target therapy remains 
unclear and needs to be determined in further investigations. Additionally, as compared 
to malignant gliomas, fluorescence-supported resection techniques might increase extend 
of tumour resection especially in cases of wide spreading dural and/ or bony infiltration 
with diffuse tumor borders. Depending on the varying fluorescence of meningiomas and 
its medicamentous persuasibility intraoperative, photodynamic therapy (PDT) might 
become a new therapeutic option especially for tumors of complex anatomical location 
like the skull base.  
13. Summary and conclusion  
Skull base meningiomas are no longer an unsolvable problem, due to technical 
advantages as well as new strategies in radio- and chemotherapy. Surgery, using all 
available technical tools, e.g. neuro-imaging, neuro-monitoring, has become effective and 
safe in aggressive tumour reduction and simultaneously in preservation of neural 
function. Moreover, even in residual, recurrent or malignant meningioma, adjuvant 
radiotherapy and prospective chemotherapy results in tumour control and sometimes in 
tumour shrinking.  
Many patients with benign skull base tumours rather accept a residual tumour in 
combination with an adjuvant therapy and a normal nerve function, than a radical tumour 
resection with the consequence of an impaired nerve function. 
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